BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AXL1717: Interim Phase I/II data

Interim data from 35 patients in the Phase I portion of the ongoing, open-label, dose-escalation, Swedish Phase I/II AXL-001 trial showed that AXL1717 was well tolerated. Additionally, Axelar said an undisclosed recommended Phase II dose...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >